Elevated Serum α-Synuclein Levels in Huntington's Disease Patients.
asymptomatic HD carriers
huntingtin
huntington’s disease
serum α-synuclein
Journal
Neuroscience
ISSN: 1873-7544
Titre abrégé: Neuroscience
Pays: United States
ID NLM: 7605074
Informations de publication
Date de publication:
01 04 2020
01 04 2020
Historique:
received:
31
08
2019
revised:
27
01
2020
accepted:
28
01
2020
pubmed:
12
2
2020
medline:
15
5
2021
entrez:
12
2
2020
Statut:
ppublish
Résumé
Recent evidence suggests a potential role for mixed proteinopathies in the development of clinical manifestations in patients with Huntington's disease (HD). A possible cross-talk between mutant huntingtin and α-synuclein aggregates has been postulated. Serum α-synuclein has been evaluated as a potential biomarker in patients with Parkinson's disease (PD). We presently sought to investigate serum α-synuclein levels in 38 HD patients (34 symptomatic and 4 premanifest) and compare them to 36 controls. We found that α-synuclein was elevated in HD patients vs. controls (2.49 ± 1.47 vs. 1.40 ± 1.16, p = 0.001). There was no difference in α-synuclein levels between symptomatic vs. premanifest HD, nor between HD patients receiving medication vs. treatment-naïve. Furthermore, α-synuclein levels showed no correlation with CAG2, Unified HD Rating Scale (UHDRS) motor score, age, disease duration or disease burden score. Our results provide evidence for elevated serum α-synuclein in HD and lend support to further investigating the role of α-synuclein in this disorder.
Identifiants
pubmed: 32045629
pii: S0306-4522(20)30067-1
doi: 10.1016/j.neuroscience.2020.01.037
pii:
doi:
Substances chimiques
alpha-Synuclein
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-39Informations de copyright
Copyright © 2020 IBRO. Published by Elsevier Ltd. All rights reserved.